Adamas: Lifshitz Law Firm, P.C. Announces Investigation of ADMS, ACBI, FLXN, and HBMD

(marketscreener.com) NEW YORK, Oct. 21, 2021 -- Adamas Pharmaceuticals, Inc. Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ADMS to Supernus Pharmaceuticals, Inc. for $8.10 in cash per share of ADMS owned. If you are an investor, and would like additional information about our...https://www.marketscreener.com/news/latest/Lifshitz-Law-Firm-P-C-Announces-Investigation-of-ADMS-ACBI-FLXN-and-HBMD--36736263/?utm_medium=RSS&utm_content=20211021